References
- Nanda N , BaoM, LinH et al. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J. Biol. Chem. 280(26) , 24680–24689 (2005).
- Kauskot A , Di Michele M, Loyen S, Freson K, Verhamme P, Hoylaerts MF. A novel mechanism of sustained platelet αIIbβ3 activation via PEAR1. Blood119(17) , 4056–4065 (2012).
- Herrera-Galeano JE , BeckerDM, WilsonAF et al. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with increased platelet aggregability. Arterioscler. Thromb. Vasc. Biol. 28(8) , 1484–1490 (2008).
- Jones CI , BrayS, GarnerSF et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 114(7) , 1405–1416 (2009).
- Faraday N , YanekLR, YangXP et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118(12) , 3367–3375 (2011).
- Johnson AD , YanekLR, ChenMH et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat. Genet. 42(7) , 608–613 (2010).
- Cui YM , WangZN, ChenXW, ZhangHL, ZhaoX, ZhouY. Pharmacokinetics and pharmacodynamics of single and multiple doses of prasugrel in healthy native Chinese subjects. Acta Pharmacol. Sin.33(11) , 1395–1400 (2012).
- Aradi D , KuliczkowskiW, AtarD, SerebruanyVL. Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. Thromb. Haemost.107(2) , 338–345 (2012).
- Alexopoulos D , PlakomytiTE, XanthopoulouI. Variability and treatment of high on-prasugrel platelet reactivity in patients with initial high on-clopidogrel platelet reactivity. Int. J. Cardiol.154(3) , 333–334 (2012).
- Mega JL , CloseSL, WiviottSD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19) , 2553–2560 (2009).
- Price MJ . Bedside evaluation of thienopyridine antiplatelet therapy. Circulation119(19) , 2625–2632 (2009).
- Price MJ , AngiolilloDJ, TeirsteinPS et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 124(10) , 1132–1137 (2011).
- Varenhorst C , JamesS, ErlingeD et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am. Heart J. 157(3) , 562.e1–9 (2009).
- Shi YY , HeL. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res.15(2) , 97–98 (2005).
▪ Websites
- SHEsis main. http://analysis.bio-x.cn
- NCBI dbSNP. www.ncbi.nlm.nih.gov/SNP